Testicular germ cell cancer (GCC) is highly curable with 5-year survival surpassing 90% ([@bib6]). This is due, in large part, to the efficacy of combination chemotherapy with bleomycin--etoposide--cisplatin (BEP) in patients with disseminated disease ([@bib11]). However, it is well established that BEP is associated with acute toxicities and increased incidence of long-term morbidities including metabolic syndrome ([@bib17]) and cardiovascular (CV) diseases ([@bib15]). The underlying mechanisms are not fully elucidated and strategies to abrogate these events have not been investigated.

Skeletal muscle is the largest organ in the human body, and the integrated properties of muscle mass and intramuscular qualities (i.e. Fibre phenotype composition, capillary density, oxidative capacity and so on) are essential for regulating whole-body homoeostasis and hence protection against metabolic disorders ([@bib28]; [@bib4]). Moreover, muscle dysfunction, as characterised by low muscle mass and/or strength, comprises an independent predictor of mortality in the general population ([@bib27]) and various malignancies ([@bib8]). Early-localised muscular fatigue and severe deconditioning are common observations in clinical practice involving GCC patients undergoing BEP therapy. Thus, BEP is likely associated with considerable impairments in muscular properties, that is, muscle fibre atrophy, loss of lean mass and impaired strength, which may predispose to adverse metabolic and/or CV late effects. However, to our knowledge, no studies to date have investigated the level and mechanisms underlying this phenomenon.

In healthy individuals, resistance training (RT) promotes widespread physiologic adaptations in all aspects of muscle function. RT, as characterised by muscle contractions against high external force, induces homoeostatic perturbations including mechanical stress, mechano-sensation and calcium flux. These stimuli activate various downstream signalling cascades ultimately promoting protein synthesis, inhibiting protein degradation and modulating muscle gene expression ([@bib10]). In concert, these adaptations result in muscle fibre hypertrophy and improved biochemical profile which translate into clinically relevant improvements in body composition, strength and control of metabolic homoeostasis ([@bib10]). Because of the capacity to improve these physiological properties, RT is considered an important concomitant strategy to the medical treatment in pathologies associated with muscle dysfunction ([@bib25]; [@bib12]). It remains unknown, however, whether such adaptations are achievable in GCC patients undergoing BEP-therapy and/or whether such adaptations are on a similar level to those observed in healthy individuals.

Against this background, we conducted the Progressive Resistance Training and Cancer Testis (PROTRACT) study to explore two major questions: (I) the effects of BEP therapy on muscle function and (II) the efficacy of RT to prevent and/or mitigate anticipated therapy-induced muscle dysfunction in GCC patients. A secondary explorative objective was to investigate the comparative efficacy of RT in GCC patients compared with healthy controls.

Materials and methods
=====================

The PROTRACT study was a prospective randomised controlled trial in patients with disseminated GCC conducted at Rigshospitalet, Copenhagen, Denmark. The overall design and methodology have been previously described ([@bib7]). In brief, patients with disseminated GCC belonging to the 'good prognostic group\' according to established international guidelines were eligible ([@bib19]). Major exclusion criteria were (i) age \<18 and \>50 years (ii) presence of clinically important CV disease (cardiomyopathy, coronary heart disease and so on), (iii) presence of chronic disease (diabetes mellitus, chronic obstructive pulmonary disease and so on) and (iv) inability to read and understand Danish. For comparison, a reference group of age- and BMI-matched healthy male individuals was recruited and screened for the same major exclusion criteria.

All subjects signed a written consent, prior to the initiation of any study-related procedures.

Therapy
-------

BEP therapy consisted of cisplatin 20 mg m^−2^ and etoposide 100 mg m^−2^ daily for 5 days and bleomycin 15 000 IE m^−2^ weekly administered in a 3-week schedule. All patients received standard antiemetic treatment with prednisolone (50 mg daily), 5HT3-antagonists and metopimazine during the initial 5 days of each cycle.

Group allocation and blinding
-----------------------------

Prior to the initiation of the study, a clinician not involved in any other study procedures used a simple coin-based procedure to generate a random list of group assignments in sequentially numbered, opaque, sealed envelopes. Thus, following all baseline assessments GCC patients were randomly allocated with a ratio of 1 : 1 to either RT intervention (INT) or usual care (CON). The healthy reference group (REF) was allocated to resistance training. Study personnel conducting the assessment and analysis of muscle biopsies (primary endpoint) were blinded to group assignment. Personnel responsible for assessments of secondary endpoints were not blinded for group allocation.

Resistance training
-------------------

RT consisted of 3 weekly supervised (hospital-based) sessions for 9 weeks, comprising four upper and lower extremity exercises: leg press, knee extension, chest press and lateral pulldown using stationary equipment (Technogym, Gambettola, Italy). For the initial five sessions, participants performed three sets of 15 repetitions at 15 repetition maximum (RM) load. From session six and onward, participants performed four sets of 10 repetitions at 10--12 RM load. Individual supervision by an instructor ensured training load was continuously increased when a participant could perform more than 12 repetitions on a given load. The number of RT sessions and the mean relative load (% of pre-training 1RM) for each exercise was calculated through all 9 weeks, and for Weeks 1--3, Weeks 4--6 and Weeks 7--9, respectively.

Usual care
----------

Participants allocated to the CON group received standard care as provided by the Department of Oncology. Patients were allowed to exercise on their own initiative, or participate in any standard care hospital- or community-based exercise programs.

Assessment timing
-----------------

All baseline assessments were conducted before the first cycle of BEP and all week 9 assessments were conducted within one week of the completion of the 3rd BEP cycle.

Primary end point
-----------------

Primary end point was change from baseline to end-of-therapy in mean muscle fibre size evaluated as the cross sectional area (*μ*m^2^) in muscle biopsies taken from musculus vastus lateralis using the Bergstrom technique ([@bib5]). Mean fibre size was also reported for type I and type II fibres, respectively. The muscle tissues were immediately mounted with Tissue-Tek (Sakura Finetek, Torrance, CA, USA) and frozen in isopentane, cooled with liquid nitrogen and stored at −80 °C. Serial sections (10 *μ*m) of the muscle biopsy samples were cut in a cryostat (−20 °C) and routine ATPase histochemistry analysis was performed after preincubation at pH 4.37, 4.60 and 10.30, as previously described ([@bib2]).

Secondary end points
--------------------

Muscle fibre phenotype distribution was assessed in biopsies and reported as the proportion (percentage) of type I fibres, while the proportion of type II fibres was sub-categorized by type IIa and type IIx ([@bib2]).

Quadriceps muscle strength was assessed by maximum isometric torque (Metitur Oy, FI-40250 Jyväskylä, Finland). Participants were seated with a fixed knee angle of 60° and performed three maximum voluntary contractions for each leg and the maximum score was recorded. The INT and REF groups also performed 1-RM tests for all exercises.

Body composition was assessed by dual energy X-ray absorptiometry scan (DPX-IQ Lunar, Lunar Corporation Madison, WI, USA) in the morning after an overnight fast. Transverse scans from head to toe measured absorption of x-ray beams at two different energy levels allowing for a valid determination of lean body mass, fat mass and fat percentage ([@bib22]).

Biochemical metabolic profile included plasma concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, glucose and insulin analysed by standard laboratory methods in blood samples drawn after an overnight fast.

Patient-reported outcomes included self-reported health-related quality of life assessed by Medical Outcomes Study Short Form-36 (MOS SF-36) ([@bib35]).

Safety was assessed by monitoring the incidence of the following clinically adverse events: postponement of BEP therapy and non-scheduled hospital visits. During RT sessions, minor adverse reactions such as discomfort, pain or nausea were also recorded.

Statistical analysis
--------------------

Eleven patients per group provided 80% power to detect a between-group difference in fibre size of 500 *μ*m^2^ (assuming a s.d. of 400 *μ*m^2^) from baseline to week 9 at the 5% significance level. Fifteen patients per group were recruited to allow for a 20% attrition rate. Baseline characteristics and incidence of adverse events were compared across groups using Mann--Withney *U*-test and Fisher\'s exact test. A random effect model including fixed effects of 'group\', 'assessment time\' and their interaction and a random effect of 'participant\' was used to analyse within-group changes from baseline to week 9. Analysis of covariance was used for between-group comparison of 'baseline-to-week 9 changes\' while adjusting for age and baseline-values. The primary analysis compared the INT and the CON group using the intention-to-treat principle including all available data, and missing observations handled according to missing-at-random assumption. A secondary analysis compared the INT and the REF groups that only included participants who had attended at least 14 RT-sessions (\>50% adherence rate). All tests were two-tailed and significance level set at 0.05.

Results
=======

Recruitment of participants took place from January 2011 to February 2013. Forty-one eligible GCC patients were contacted, and 30 (73%) were randomised. The study flow is presented in [Figure 1](#fig1){ref-type="fig"}. Participant characteristics were balanced at baseline ([Table 1](#tbl1){ref-type="table"}). Twenty-five (83%) participants completed week 9 assessments (CON group, *n*=13; INT group, *n*=12). Overall, the INT group attended a mean of 18.9 RT sessions (70% range: 0--100%).

There were no differences in clinical adverse events. Twenty-nine non-severe adverse reactions were observed in the INT group during RT, and on 25 occasions (∼10% of all sessions) a participant discontinued the session because of discomfort.

Primary comparison: changes for GCC Patients by randomised group
----------------------------------------------------------------

### Primary end point

Intention-to-treat analysis showed that the muscle fibre size decreased by −322 *μ*m^2^ (95% confidence interval (CI): −899 to 255; *P*=0.473) in the CON group and increased by +206 *μ*m^2^ (95% CI: −384 to 796; *P*=0.257) in the INT group (adjusted mean difference (AMD), +625 *μ*m^2^, 95% CI: −253 to 1503, *P*=0.149). Type I fibre size decreased by −209 *μ*m^2^ in the CON group and by −5 *μ*m^2^ in the INT group (AMD, +449 *μ*m^2^, *P*=0.386). Type II fibre size decreased by −495 *μ*m^2^ in the CON group and increased by +424 *μ*m^2^ in the INT group (AMD, +823 *μ*m^2^, *P*=0.092) ([Figure 2](#fig2){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}).

### Secondary end points

Whole-body lean mass decreased by −2.56 kg (*P*\<0.001) in the CON group and by −1.34 kg (*P*=0.041) in the INT group (AMD, +1.49 kg, *P*=0.07). Isometric strength decreased by −21 Nm (*P*=0.008) in the CON group and by −5 Nm (*P*=0.527) in the INT group ([Table 2](#tbl2){ref-type="table"}, [figure 3](#fig3){ref-type="fig"}).

Total plasma cholesterol increased by +0.7 m[M]{.smallcaps} (*P*=0.013) in the CON group and by +1.0 m[M]{.smallcaps} (*P*\<0.001) in the INT group (AMD, +0.6 m[M]{.smallcaps}, *P*=0.215). LDL cholesterol increased by +0.6 m[M]{.smallcaps} (*P*=0.28) in the CON group and by +1.0 m[M]{.smallcaps} (*P*\<0.001) in the INT group (AMD, +0.5 m[M]{.smallcaps}, *P*=0.175) and triglycerides increased by +0.94 m[M]{.smallcaps} (*P*\<0.001) in the INT group ([Figure 4](#fig4){ref-type="fig"}, [Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Patient reported that physical health decreased by −12.2 points (*P*\<0.001) in the CON group and by −11.4 points (*P*\<0.001) in the INT group (AMD; +1.11 points, *P*=0.801). The between-group difference for the 'role emotional\' subscale in favour of the INT group approached significance (AMD, +38, *P*=0.054) ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Secondary comparison: efficacy of resistance training in GCC patients *vs* healthy controls
-------------------------------------------------------------------------------------------

Ten patients (66%) in the INT group performed ⩾14 RT sessions with mean adherence of 22.6 sessions (84%). This was similar to the REF group (mean 21.2 sessions (78%)). In three of the four exercises, the REF group had higher average training load ([Supplementary Table S3](#sup1){ref-type="supplementary-material"})

The REF group improved muscle fibre size (all fibres, +768 *μ*m^2^; type I fibres, +631 *μ*m^2^; type II fibres, +1061 *μ*m^2^, all *P*\<0.05), but the changes were not significantly different compared with changes observed in the INT group for all fibres (AMD, −834 *μ*m^2^, *P*=0.105), type I fibres (AMD, −802 *μ*m^2^, *P*=0.12) or type II fibres (AMD, −907 *μ*m^2^, *P*=0.122) ([Table 2](#tbl2){ref-type="table"}).

The REF group improved muscle fibre phenotype composition, capillary density, lean mass, isometric strength and fat percentage ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Significant between-group differences in favour of the REF group were seen for type I proportion (AMD +10.7%, *P*=0.042), type IIx proportion (AMD, −7.2%, *P*=0.047), capillary density (AMD +0.6 cap. per fibre, *P*=0.005), lean mass (AMD, +2.67 kg, *P*\<0.001) compared with the INT group ([Table 2](#tbl2){ref-type="table"}). Also, significant between-group differences in favour of the REF group were found for fat percentage (AMD, +3.1%, *P*=0.002), total cholesterol (AMD, −1.3 m[M]{.smallcaps}, *P*\<0.001), LDL cholesterol (AMD, −1.1 m[M]{.smallcaps}, *P*\<0.001), triglycerides (AMD, −1.00 m[M]{.smallcaps}, *P*=0.008) and insulin (AMD, −16 pM, *P*=0.008) ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Muscle dysfunction is considered a candidate mechanism associated with incidence and prognosis of metabolic syndrome and CV events in the general population ([@bib29]; [@bib27]). Evidence showing GCC survivors treated with BEP have increased incidence of these conditions, provided a strong rationale to investigate the effects of BEP on muscular function and whether this could be mitigated by RT. Our principal finding was that BEP was associated with negative changes across various muscular end points, in parallel with unfavourable changes in lipid metabolic profile and quality of life. Moreover, RT was safe, feasible and attenuated BEP-induced dysfunction in selected end points, but BEP blunted several RT-induced adaptations in muscle function.

An important finding was that 9 of 10 evaluable patients in the CON group had reduced mean muscle fibre size after therapy, and also displayed trends toward qualitative changes in phenotype distribution with an average increase of +6% in the proportion of glycolytic type IIx fibres. Increased proportion of this glycolytic phenotype has been found to be highly expressed in subjects with poor insulin sensitivity ([@bib23]). Although not statistically significant, this data to our knowledge is the first to indicate that systemic anti-cancer treatment may be associated with unfavourable changes in muscle fibre morphology on a cellular level. Also, the reduction in lean mass (∼2.5 kg) in the CON group was larger than what has been observed during 6 months of sorafenib therapy for advanced stage renal cell carcinoma ([@bib3]). It is arguably not possible to identify a single, major deteriorating factor in a clinical setting, which uses a combination of three anti-neoplastic agents. Cisplatin may, however, comprise a primary culprit, as studies have shown this stimulates induction of muscle atrophy-related genes, proteosomal proteolysis, and inflammation through the NF-*κ*B signalling pathway *in vitro* ([@bib13]). Moreover, cisplatin is neurotoxic possibly inhibiting motorunit neural drive ([@bib26]), which in turn may cause atrophy and changes toward glycolytic phenotypes.

Given the detrimental impact of BEP on muscle function, an important finding of the present study was that supervised progressive RT was safe and feasible during BEP. Overall, mean adherence rate to RT was concordant with previously supervised exercise trials during chemotherapy ([@bib9]; [@bib1]) and RT did not increase (nor reduce) the number of clinical adverse events. GCC patients are treated with relatively high chemotherapeutic doses that may cause myelosuppression and increased risk of neutropenia/infections ([@bib14]). Therapy complications did render two patients unable to perform RT, and ∼10% of all RT sessions were discontinued due to minor adverse reactions, that is, nausea, dizziness or pain. Thus, demonstration of the overall feasibility and safety of progressive RT in the present context is novel and important, but this also emphasises that individual monitoring and collaboration with oncologists is imperative to minimise the risk of compromising therapy administration and/or augmenting BEP-related side effects.

For intention-to-treat analyses, we found no significant differences between the INT and CON group, although trends across several end points indicated that RT in the present setting attenuated the level of muscle dysfunction. The between-group differences for changes in muscle fibre size actually exceeded our *a priori* target (+500 *μ*m^2^) but remained non-significant due, at least in part, to larger-than-expected within-group variation. No studies are available for direct comparison as muscle fibre assessments have not been previously performed in the exercise oncology setting, but the difference in lean mass change (∼1.5 kg), was comparable with or larger than that of previous RT trials during anticancer therapy ([@bib16]; [@bib34]). Moreover, the INT group maintained their pretreatment in isometric quadriceps strength, whereas the CON group significantly decreased in muscle strength, and the INT group also significantly improved muscle strength (+28%) evaluated by 1RM test. This suggests, that 9 weeks (∼19 sessions) of progressive RT in GCC patients during BEP had a comparable effect on muscle strength as RT interventions with higher volume (12--52 weeks duration) in other malignancies ([@bib34]).

In both GCC groups, we found trends toward increased adiposity and significant increases in plasma lipid concentrations, which are known to be strongly associated with the risk of developing metabolic disorders and CV events ([@bib24]). [@bib32] showed that an increase of ∼1 m[M]{.smallcaps} in total cholesterol (similar to what we found in the present study) was associated with age- and race-adjusted relative risk of 1.34 in men for developing coronary heart disease. It should be noted, however, that a recent study in GCC patients showed that lipid concentrations 9 months post therapy were similar to pre-treatment levels ([@bib36]), which questions whether this acute rise in lipid concentrations is involved in the onset of late disorders.

We found similar changes in patient-reported quality of life in both GCC groups with reductions in the physical component scale (∼12 points) and several subscales of the SF-36-questionnaire. The trend toward improvement of the 'emotional role\' subscale in favour of the INT group should be interpreted with care, but is in accordance with a large body of evidence showing participation in exercise programs can improve psycho-social end points in the oncology setting ([@bib31]; [@bib30]).

The clinical implications of our findings remain to be determined. It is noteworthy, however, that incidence rates of chronic disorders are strongly associated with age-related decline in muscle function (sarcopenia), which onsets in the 6th life decade and accounts for an estimated loss of 1.9 kg lean mass per decade ([@bib20]). From a muscle physiological perspective, the reduction in lean mass observed in GCC patients during 9 weeks of BEP therapy appears to be equivalent to more than a decade of physiological aging. Interestingly, this relative decline is comparable with the reduction in cardio pulmonary exercise capacity shown in women undergoing chemotherapy for early-stage breast cancer ([@bib18]). Although a proportion of patients may recover this deficit spontaneously after completion of therapy, some individuals potentially struggle to return to their preillness level ([@bib21]), emphasising the need for countermeasures protecting against therapy-related physiological deterioration.

Within the field of exercise oncology, the safety and efficacy of structured exercise have been investigated across various diagnoses and settings ([@bib30]). Despite the rapidly growing body of evidence supporting the application of exercise in the oncology setting, it remains relatively poorly explored to what extend cancer and its treatments influence the adaptation response to exercise training. Thus, an important finding of the present study was that patients undergoing cytotoxic therapies, for several outcomes were not equally responsive to RT as their age-matched healthy counterparts. As expected, we found RT-induced improvements in the healthy REF group across all measures of muscle function. Compared with these wide-ranging positive effects, we found the changes in the INT group were either considerably blunted or in some cases abolished, which suggests that BEP may alter muscle malleability to contractile activity. The difference in response may, at least in part, be attributed to the fact that the REF group had significantly higher average training load. Also, the concomitant administration of corticoid-steroids, which is known to cause various unfavourable muscular effects, may inhibite anabolic pathways involved in hypertrophy ([@bib33]). In concert, our findings suggests that while RT-induced improvements in muscle function may be achievable in some GCC patients, the effects cannot be predicted during BEP, which limits the general applicability of resistance training in this clinical context.

The present study has important limitations, first and foremost the relatively small sample size and a considerable number of statistical tests increasing the risk of type I and type II errors. Second, we did not control for use of antiemetic treatment. Patients are prescribed the same absolute dose of prednisolone, which may have influenced the physiological impact on skeletal muscle, since doses relative to body weight/body surface area differed. Finally, there was likely a case of selection bias, as the present study appealed to participants motivated for exercise, and also there was risk of bias associated with certain assessments, as personnel responsible for secondary end points were not blinded to group assignment.

In summary, BEP was associated with significant reductions in lean mass and strength and trends toward atrophy and an unfavourable phenotype composition in patients with GCC, in parallel with negative changes in metabolic profile. Hospital-based, supervised RT was safe and attenuated the reduction in fibre size, lean mass and strength, but BEP blunted several positive RT adaptations found in healthy subjects. Since GCC patients undergoing BEP were not equally responsive to RT as healthy individuals, and RT did not protect against changes in metabolic homoeostasis, our study does not support the general application of resistance training in this setting, but larger-scaled trials are required to confirm our findings. Also, prospective follow-up studies are needed to explore whether the considerable level of therapy-induced muscle dysfunction found immediately after the completion of treatment plays a role in the onset of long-term disorders among GCC survivors.
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###### 

Click here for additional data file.

![**Trial design.** Available data (*n*) for each assessment method at week 9 is presented by study group.](bjc2014273f1){#fig1}

![**Individual changes in muscle fibre size (cross sectional area).** Waterfall plot: red bars represent individual reduction in fibre size (atrophy), blue bars represent individual increase in fibre size (hypertrophy). Note: overall, seven muscle biopsy samples (from different individuals) were of poor quality and were not valid for fibre size analysis, thus only 10 (CON), 9 (INT) and 12 (REF) individuals with evaluable baseline and week-9 biopsies are presented in this figure.](bjc2014273f2){#fig2}

![**Within-group changes in secondary muscular end points.** Random effect model-based within-group mean changes (s.e.m.) from baseline to week 9 based on all available data presented for (**A**) proportion of muscle fibre phenotypes: type I /type IIa/type IIx; (**B**) whole-body lean mass, (**C**) capillaries per fibre; (**D**) isometric quadriceps strength. \* denotes within-group change significantly different from zero, *P*\<0.05. Abbreviations: cap=capillaries; LBM=lean body mass.](bjc2014273f3){#fig3}

![**Within-group changes in selected metabolic end points.** Random effect model-based within-group mean changes (s.e.m.) from baseline to week 9 based on all available data presented for (**A**) plasma lipid concentrations: Total cholesterol/HDL cholesterol/LDL cholesterol/triglycerides; (**B**) fat mass/fat percentage. \* denotes within-group change significantly different from zero, *P*\<0.05. Abbreviations: HDL=high-density lipoprotein; LDL=low-density lipoprotein; pct=percentage; T-CHOL=total cholesterol; Tri=triglycerides.](bjc2014273f4){#fig4}

###### Baseline characteristics of study participants

                                                     **Usual care control group (CON),** ***n*****=15**   **Resistance training group (INT),** ***n*****=15**   **Healthy reference group (REF),** ***n*****=19**
  ------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------
  Age, years (s.d.)                                                      35.8 (8.9)                                           34.4 (7.6)                                           31.5 (6.0)
  Body mass index, kg m^−2^ (s.d.)                                       24.2 (3.2)                                           24.0 (3.7)                                           24.2 (5.0)
  **Smoking**                                                                                                                                                  
   Current smoker, no. (%)                                                2 (13%)                                               0 (0%)                                               3 (16%)
   Former smoker, no. (%)                                                 5 (33%)                                               5 (33%)                                              9 (47%)
  **Physical activity level**                                                                                                                                  
  Sedentary[a](#t1-fn3){ref-type="fn"}, no. (%)                           8 (53%)                                               7 (47%)                                             11 (58%)
  **Diagnosis**                                                                                                                                                
  Seminoma, no. (%)                                                       7 (47%)                                               7 (47%)                                                NA
  Non-seminoma, no. (%)                                                   8 (53%)                                               8 (53%)                                                NA
  Elevated tumour-markers, no. (%)                                        8 (53%)                                               7 (47%)                                                NA
   Elevated AFP, no. (%)                                                  4 (27%)                                               3 (20%)                                                NA
   Elevated HCG, no. (%)                                                  8 (53%)                                               6 (40%)                                                NA
  **Orchiectomy**                                                                                                                                              
  Days from surgery, median (interquartile range)                      130 (35--336)                                        185 (78--1618)                                             NA
  Bilateral[b](#t1-fn4){ref-type="fn"}, no. (%)                            1 (7%)                                               2 (13%)                                                NA
  Unilateral, no. (%)                                                     14 (93%)                                             13 (87%)                                                NA
  **Gonadal status, serum**                                                                                                                                    
  Testosterone, nmol l^−1^                                               17.0 (4.9)                                           18.8 (6.5)                                               NA
  FSH, IU l^−1^                                                          9.0 (12.6)                                            6.4 (7.3)                                               NA
  LH, IU l^−1^                                                           4.3 (3.6)                                             2.2 (1.9)                                               NA

Abbreviations: AFP=alfa-phetoprotein; FSH=follicle-stimulating hormone; HCG=human chorionic gonadotropin beta-chains; LH=luteinizing hormone; NA=not available.

Continuous variables are reported as mean (s.d.) and categorical variables are reported as numbers (%). There were no significant differences between groups (*P*\>0.05).

'Sedentary\' is defined as 'performing less than 150 min of moderate intensity physical activity per week\'.

Standard management of patients with bilateral orchiectomy includes testosterone substitution, but none of the patients included in this study had testosterone levels outside of the normal range at the point of inclusion.

###### Effects on muscle end points

                                          **Baseline**   **Week 9**   **Within-group change**   **Adjusted between-group difference**                                                                                 
  -------------------------------------- -------------- ------------ ------------------------- --------------------------------------- ------- ---------------- ------------- -------------- ------- ---------------- -------------
  **CSA, all fibres, ***μ***m^2^**                                                                                                                                                                                    
  CON                                         4576          1028               4272                              605                   −322      −899 to 255    0.473          *INT vs CON*  625       −253 to 1503   0.149
  INT                                         4877          812                5190                             1108                   206       −384 to 796    0.257                                                  
  REF                                         5057          1363               5848                             1670                   768       194 to 1341    **0.011**      *INT vs REF*  −834      −1862 to 195   0.105
  **CSA, type I fibres, ***μ***m^2^**                                                                                                                                                                                 
  CON                                         4439          1226               4241                              908                   −209      −877 to 460    0.520          *INT vs CON*  449       −583 to 1481   0.368
  INT                                         4931          1010               4943                             1241                   −5        −690 to 681    0.988                                                  
  REF                                         4799          1339               5355                             1350                   631        37 to 1225    **0.038**      *INT vs REF*  −802      −1836 to 232   0.120
  **CSA, type II fibres, ***μ***m^2^**                                                                                                                                                                                
  CON                                         4854          1241               4445                              488                   −495      −1161 to 172   0.137          *INT vs CON*  823       −151 to 1797   0.092
  INT                                         4925          817                5498                             1361                   424       −258 to 1106   0.208                                                  
  REF                                         5174          1432               6319                             1740                   1061     413 to --1709   **0.003**      *INT vs REF*  −907      −2083 to 270   0.122
  **Proportion type I, %**                                                                                                                                                                                            
  CON                                         44.2          14.2               42.7                             18.9                   −3.0      −10.2 to 4.2   0.389          *INT vs CON*  0.0      −10.8 to 10.9   0.993
  INT                                         44.7          17.2               44.1                             13.7                   −3.5      −10.6 to 3.7   0.324                                                  
  REF                                         40.8          15.1               49.7                             12.4                   10.3      3.5 to 17.0    **0.004**      *INT vs REF*  −10.7    −21.0 to −0.4   **0.042**
  **Proportion type IIa, %**                                                                                                                                                                                          
  CON                                         40.0          16.3               35.3                             11.1                   −2.9      −9.2 to 3.4    0.347          *INT vs CON*  5.7       −2.7 to 14.0   0.171
  INT                                         36.6          12.9               39.0                             14.2                   4.5       −1.8 to 10.7   0.155                                                  
  REF                                         42.6          12.7               43.4                              9.3                   −0.7      −6.6 to 5.3    0.816          *INT vs REF*  3.1       −6.3 to 12.5   0.495
  **Proportion type IIx, %**                                                                                                                                                                                          
  CON                                         15.8          13.0               22.0                             14.4                   6.0       −1.0 to 13.0   0.087          *INT vs CON*  −5.7      −16.0 to 4.4   0.244
  INT                                         18.6          10.0               16.9                              9.3                   −1.2      −8.1 to 5.7    0.727                                                  
  REF                                         16.6          10.0                6.9                              8.2                   −9.5     −14.4 to −4.6   **\<0.001**    *INT vs REF*  7.2       0.3 to 14.0    **0.047**
  **Cap. per fibre, no.**                                                                                                                                                                                             
  CON                                         1.84          0.52               1.74                             0.28                   −0.09    −0.29 to 0.11   0.379          *INT vs CON*  −0.03    −0.36 to 0.29   0.839
  INT                                         2.02          0.37               1.92                             0.45                   −0.20     −0.41 to 0.0   0.055                                                  
  REF                                         2.17          0.53               2.64                             0.84                   0.40      0.17 to 0.63   **0.002**      *INT vs REF*  −0.60    −1.00 to −0.20  **0.005**
  **Lean mass, kg**                                                                                                                                                                                                   
  CON                                        61.04          5.39               58.85                            4.19                   −2.56    −3.78 to −1.33  **\<0.001**    *INT vs CON*  1.46     −0.14 to 3.07   0.073
  INT                                        60.84          8.18               60.06                            8.05                   −1.34    −2.62 to −0.06  **0.041**                                              
  REF                                        59.62          8.22               61.25                            9.04                   1.82      0.98 to 2.66   **\<0.001**    *INT vs REF*  −2.67    −4.08 to −1.25  **\<0.001**
  **Quadriceps strength, Nm**                                                                                                                                                                                         
  CON                                         223            36                 195                              39                    −21        −37 to −6     **0.008**      *INT vs CON*  11         −15 to 39     0.399
  INT                                         247            59                 249                              66                    −5         −22 to 11     0.527                                                  
  REF                                         253            62                 262                              67                    12           4 --20      **0.004**      *INT vs REF*  −11         −24 to 3     0.109
  **1−RM leg press, kg**                                                                                                                                                                                              
  CON                                         N.A                               NA                                                     NA                                      *INT vs CON*  NA                        
  INT                                         155            38                 194                              41                    43           31--55      **\<0.001**                                            
  REF                                         141            53                 184                              48                    49           40--60      **\<0.001**    *INT vs REF*  −6         −23 to 11     0.449

Abbreviations: Cap=capillaries; CI=confidence interval; CON=usual care control group; CSA=cross sectional area; INT=resistance training group; Nm=newtonmetre; REF=healthy reference group; RzM=repetition maximum.

Note. means (s.d.) at week 9 are based on available data. Within-group change may not precisely reflect this difference given that mean change is estimated based on mixed-model analysis. Group differences in mean change were adjusted for baseline value of the end point and age. Two separate analyses are presented: *INT vs CON:* primary adjusted analysis between the two germ cell cancer groups based on 'intention-to-treat analysis\' including all available data. *INT vs REF:* secondary adjusted analysis between the two RT groups included only participants who performed ⩾14 RT sessions; thus two germ cell cancer patients (with 0 sessions) were excluded from this analysis. Bold entries are for *P*-values below the significant level.
